Journals Metabolism: Clinical and Exper...

Metabolism: Clinical and Experimental
Khaled Alabduljabbar, Carel W le Roux
Diabetes is a chronic disease that affects a vast number of individuals globally, and without optimal treatment, can lead to significant health complications. Moreover, obesity is another chronic disease with several complications, which includes type 2 diabetes. Bariatric surgery is a viable long-term choice for managing diseases such as obesity and type 2 diabetes. However, the impact of pharmacotherapy before and after surgery remains unclear. In this review, we assessed the use of pharmacotherapy in patients with obesity with or without diabetes before and after bariatric surgery, focusing on weight loss, glycemic control, and the risk of postoperative complications...
September 18, 2023: Metabolism: Clinical and Experimental
Yan Tao, Jingyuan Zhao, Jilong Yin, Zixin Zhou, Huijie Li, Jinhao Zang, Tianci Wang, Yalin Wang, Chun Guo, Faliang Zhu, Shen Dai, Fuwu Wang, Hui Zhao, Haiting Mao, Fengming Liu, Lining Zhang, Qun Wang
BACKGROUND: The liver regulates metabolic balance during fasting-feeding cycle. Hepatic adaptation to fasting is precisely modulated on multiple levels. Tumor necrosis factor-α-induced protein 8-like 2 (TIPE2) is a negative regulator of immunity that reduces several liver pathologies, but its physiological roles in hepatic metabolism are largely unknown. METHODS: TIPE2 expression was examined in mouse liver during fasting-feeding cycle. TIPE2-knockout mice, liver-specific TIPE2-knockout mice, liver-specific TIPE2- overexpressed mice were examined for fasting blood glucose and pyruvate tolerance test...
September 15, 2023: Metabolism: Clinical and Experimental
Michail Kokkorakis, Angeliki Katsarou, Niki Katsiki, Christos S Mantzoros
The 21st century is characterized by an increasing incidence and prevalence of obesity and the burden of its associated comorbidities, especially cardiometabolic diseases, which are reaching pandemic proportions. In the late '90s, the "black box" of adipose tissue and energy homeostasis was opened with the discovery of leptin, transforming the adipose tissue from an "inert fat-storage organ" to the largest human endocrine organ and creating the basis on which more intensified research efforts to elucidate the pathogenesis of obesity and develop novel treatments were based upon...
September 7, 2023: Metabolism: Clinical and Experimental
Eyun Song, Soon Young Hwang, Min Jeong Park, Ahreum Jang, Kyeong Jin Kim, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Kyung Mook Choi
OBJECTIVE: Diabetes mellitus (DM) and sarcopenia (SP) are growing public health concerns in an aging society, which share common pathophysiological mechanisms and are associated with serious health consequences. We investigated the impact of DM and SP on all-cause and cardiovascular mortalities in a longitudinal nationwide population-based study. METHODS: The study analyzed data from the Korea National Health and Nutrition Examination Survey conducted between 2008 and 2011, including information on appendicular skeletal muscle mass data...
August 21, 2023: Metabolism: Clinical and Experimental
Shenghui Chen, Xinyu Wang, Zhening Liu, Jinghua Wang, Yanjun Guo, Qinqiu Wang, Hangkai Huang, Youming Li, Chaohui Yu, Chengfu Xu
BACKGROUND & AIMS: Olfactomedin 4 (OLFM4) is a glycoprotein that is related to obesity and insulin resistance. This study aims to investigate the role and mechanisms of OLFM4 in nonalcoholic fatty liver disease (NAFLD). APPROACH & RESULTS: OLFM4 expression levels were significantly increased in liver samples from NAFLD patients and in cellular and mouse models of NAFLD. Cell lines deficient in or overexpressing OLFM4 and Olfm4-/- mice were established to study its role in NAFLD...
August 21, 2023: Metabolism: Clinical and Experimental
Stergios A Polyzos, Ilias D Vachliotis, Christos S Mantzoros
Nonalcoholic fatty liver disease (NAFLD), sarcopenia and sarcopenic obesity (SO) are highly prevalent conditions that may coexist, especially in the aging population, without any approved pharmacologic treatment for all of them. There are multiple pathophysiologic mechanisms suggested to explain an association between NAFLD and sarcopenia or SO, including alterations in the adipokines, cytokines, hepatokines and myokines, which may interplay with other factors, such as aging, diet and physical inactivity. In clinical terms, most observational studies support an association between NAFLD and sarcopenia or SO; importantly, there are few cohort studies indicating higher mortality in patients with NAFLD and sarcopenia...
August 4, 2023: Metabolism: Clinical and Experimental
Rahim Ullah, Yi Shen, Yu-Dong Zhou, Junfen Fu
Over the past few decades, there has been a global increase in childhood obesity. This rise in childhood obesity contributes to the susceptibility of impaired metabolism during both childhood and adulthood. The hypothalamus, specifically the arcuate nucleus (ARC), houses crucial neurons involved in regulating homeostatic feeding. These neurons include proopiomelanocortin (POMC) and agouti-related peptide (AGRP) secreting neurons. They play a vital role in sensing nutrients and metabolic hormones like insulin, leptin, and ghrelin...
August 4, 2023: Metabolism: Clinical and Experimental
Matina Kouvari, Laura Valenzuela-Vallejo, Valentina Guatibonza-Garcia, Stergios A Polyzos, Yixiang Deng, Michail Kokkorakis, Melih Agraz, Sophia C Mylonakis, Angeliki Katsarou, Ornella Verrastro, Georgios Markakis, Mohammed Eslam, Georgios Papatheodoridis, Jacob George, Geltrude Mingrone, Christos S Mantzoros
BACKGROUND: Non-invasive tools (NIT) for non-alcoholic fatty liver disease (NAFLD) screening or diagnosis need to be thoroughly validated using liver biopsies. PURPOSE: To externally validate NITs designed to differentiate the presence or absence of liver steatosis as well as more advanced disease stages, to confirm fully validated indexes (n = 7 NITs), to fully validate partially validated indexes (n = 5 NITs), and to validate for the first time one new index (n = 1 NIT)...
July 30, 2023: Metabolism: Clinical and Experimental
Rong Liu, Mingping Qian, Ying-Yu Cui
Protein kinases (PKs), one of the largest protein families, can be further divided into different groups based on their substrate or structure and function. PKs are important signaling messengers in numerous life activities, including cell metabolism, proliferation, division, differentiation, senescence, death, and disease. Among PK-related diseases, nonalcoholic fatty liver disease (NAFLD) has been recognized as a major contributor to hepatocellular carcinoma (HCC) and liver transplantation. Unfortunately, NAFLD-derived HCC (NAFLD-HCC) has poor prognosis because it is typically accompanied by older age, multiple metabolic syndromes, obstacles in early-stage diagnosis, and limited licensed drugs for treatment...
July 28, 2023: Metabolism: Clinical and Experimental
Weixing Wen, Haoxiao Zheng, Weiwen Li, Guolin Huang, Peng Chen, Xiaolin Zhu, Yue Cao, Jiahuan Li, Xiaohui Huang, Yuli Huang
With the worldwide pandemic of metabolic diseases, such as obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD), cardiometabolic disease (CMD) has become a significant cause of death in humans. However, the pathophysiology of metabolic-associated cardiac injury is complex and not completely clear, and it is important to explore new strategies and targets for the treatment of CMD. A series of pathophysiological disturbances caused by metabolic disorders, such as insulin resistance (IR), hyperglycemia, hyperlipidemia, mitochondrial dysfunction, oxidative stress, inflammation, endoplasmic reticulum stress (ERS), autophagy dysfunction, calcium homeostasis imbalance, and endothelial dysfunction, may be related to the incidence and development of CMD...
July 28, 2023: Metabolism: Clinical and Experimental
Michail Kokkorakis, Chrysoula Boutari, Niki Katsiki, Christos S Mantzoros
No abstract text is available yet for this article.
July 28, 2023: Metabolism: Clinical and Experimental
Eva M Fernández-Sáez, Maite Losarcos, Sara Becerril, Víctor Valentí, Rafael Moncada, Marina Martín, María A Burrell, Victoria Catalán, Javier Gómez-Ambrosi, Carmen Mugueta, Inmaculada Colina, Camilo Silva, Javier Escalada, Gema Frühbeck, Amaia Rodríguez
BACKGROUND: The biological mediators supporting the resolution of liver steatosis, inflammation and fibrosis after bariatric surgery in patients with obesity and NAFLD remain unclear. We sought to analyze whether uroguanylin and guanylin, two gut hormones involved in the regulation of satiety, food preference and adiposity, are involved in the amelioration of obesity-associated NAFLD after bariatric surgery. METHODS: Proguanylin (GUCA2A) and prouroguanylin (GUCA2B) were measured in 214 participants undergoing bariatric surgery with biopsy-proven NAFLD diagnosis...
July 28, 2023: Metabolism: Clinical and Experimental
Yuntao Hu, Jing Li, Xin Li, Di Wang, Rui Xiang, Wenjun Liu, Song Hou, Qinghe Zhao, Xiaoxing Yu, Ming Xu, Dong Zhao, Tao Li, Yujing Chi, Jichun Yang
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide; however, the underlying mechanisms remain poorly understood. FAM3D is a member of the FAM3 family; however, its role in hepatic glycolipid metabolism remains unknown. Serum FAM3D levels are positively correlated with fasting blood glucose levels in patients with diabetes. Hepatocytes express and secrete FAM3D, and its expression is increased in steatotic human and mouse livers. Hepatic FAM3D overexpression ameliorated hyperglycemia and steatosis in obese mice, whereas FAM3D-deficient mice exhibited exaggerated hyperglycemia and steatosis after high-fat diet (HFD)-feeding...
July 14, 2023: Metabolism: Clinical and Experimental
Ya-Di Wang, Liang-Liang Wu, Yun-Ni Mai, Kai Wang, Yi Tang, Qi-Yu Wang, Jiao-Yang Li, Li-Yan Jiang, Zhe-Zhen Liao, Can Hu, Yuan-Yuan Wang, Jing-Jing Liu, Jiang-Hua Liu, Xin-Hua Xiao
BACKGROUND AND OBJECTIVES: MicroRNA-dependent regulation of hepatic lipid metabolism has been recognized recently as a key pathological mechanism contributing to the development of NAFLD. However, whether miR-32-5p (miR-32) plays a role in lipid metabolism or contributes to NAFLD remains unclear. METHODS AND RESULTS: A marked increase in miR-32 expression was observed in liver samples from patients and mice with NAFLD, as well as in palmitate-induced hepatocytes...
July 12, 2023: Metabolism: Clinical and Experimental
Amirhossein Sahebkar, Zahra Foroutan, Niki Katsiki, Tannaz Jamialahmadi, Christos S Mantzoros
One of the newly recognized types of cell death is ferroptosis which is related to the accumulation of iron and lipid-reactive oxygen species. Ferroptosis is considered a programmed cell death with a different mechanism from apoptosis, necrosis, and autophagy. Emerging evidence suggests that ferroptosis may occur in the context of cardiovascular disease (CVD), cancer, neurodegenerative diseases, and non-alcoholic fatty liver disease (NAFLD). Statins are the first-line therapy for dyslipidemia. The suppression of the HMG-CoA reductase by statins leads to decreased expression of glutathione peroxidase 4 (GPX4), a key regulator of lipid peroxidation, which in turn results in lipid ROS production and induction of ferroptosis...
July 11, 2023: Metabolism: Clinical and Experimental
Yunfeng Shen, Lidan Cheng, Minxuan Xu, Wei Wang, Zhiping Wan, Haixia Xiong, Wanrong Guo, Mengyin Cai, Fen Xu
BACKGROUND AND RATIONALE: Activation of hepatic stellate cells (HSCs), the central event of fibrosis, indicates the severe stage of non-alcoholic fatty liver disease (NAFLD). MicroRNAs (miRNAs) participate in this process. Treatment with a sodium-glucose cotransporter 2 inhibitor (SGLT2i) alleviates liver fibrosis in patients with type 2 diabetes and NAFLD; however, the role of SGLT2i in ameliorating liver fibrosis in NAFLD by regulating miRNAs remains unclear. APPROACH AND RESULTS: We monitored the expression of NAFLD-associated miRNAs in the livers of two NAFLD models and observed high expression of miR-34a-5p...
July 6, 2023: Metabolism: Clinical and Experimental
Yi Zhang, Yanhui Li, Yang Liu, Hongzhi Wang, Yingli Chen, Bing Zhang, Meiqi Song, Lei Song, Qinchao Ding, Jiannan Qiu, Mingjian Fan, Lihui Qu, Zhigang Wang
BACKGROUND AND AIMS: Hepatosteatosis is one of the early features of alcoholic liver disease (ALD) and pharmaceutical or genetic interfering of the development of hepatosteatosis will efficiently alleviate the progression of ALD. Currently, the role of histone methyltransferase Setdb1 in ALD is not yet well understood. METHOD: Lieber-De Carli diet mice model and NIAAA mice model were constructed to confirm the expression of Setdb1. The hepatocyte-specific Setdb1-knockout (Setdb1-HKO) mice was established to determine the effects of Setdb1 in vivo...
July 5, 2023: Metabolism: Clinical and Experimental
Ann-Cathrin Koschker, Bodo Warrings, Caroline Morbach, Florian Seyfried, Pius Jung, Ulrich Dischinger, Frank Edelmann, Martin J Herrmann, Christine Stier, Stefan Frantz, Uwe Malzahn, Stefan Störk, Martin Fassnacht
OBJECTIVE: Randomized evidence comparing the cardiovascular effects of surgical and conservative weight management is lacking. PATIENTS & METHODS: In this single-center, open-label randomized trial, obese patients with indication for Roux-en-Y gastric bypass (RYGB) and able to perform treadmill cardiopulmonary exercise testing (CPET) were included. After a 6-12 month run-in phase of multimodal anti-obesity treatment, patients were randomized to RYGB or psychotherapy-enhanced lifestyle intervention (PELI) and co-primary endpoints were assessed 12 months later...
June 30, 2023: Metabolism: Clinical and Experimental
Eui Jung Jung, Ki Woon Sung, Tae Hyun Bae, Hee-Yeon Kim, Ha Rim Choi, Sung Hyun Kim, Chan Hoon Jung, Su Ran Mun, Yeon Sung Son, Shin Kim, Young Ho Suh, Anna Kashina, Joo-Won Park, Yong Tae Kwon
BACKGROUND AND AIMS: Central to the pathogenesis of nonalcoholic fatty liver disease (NAFLD) is the accumulation of lipids in the liver and various fat tissues. We aimed to elucidate the mechanisms by which lipid droplets (LDs) in the liver and adipocytes are degraded by the autophagy-lysosome system and develop therapeutic means to modulate lipophagy, i.e., autophagic degradation of LDs. METHODS: We monitored the process in which LDs are pinched off by autophagic membranes and degraded by lysosomal hydrolases in cultured cells and mice...
June 27, 2023: Metabolism: Clinical and Experimental
Panpan He, Yanjun Zhang, Ziliang Ye, Huan Li, Mengyi Liu, Chun Zhou, Sisi Yang, Xiaoqin Gan, Yuanyuan Zhang, Xianhui Qin
BACKGROUND: The association of a healthy lifestyle and the American Heart Association (AHA) Life's Essential 8 (LE8) score with the risk of new-onset nonalcoholic fatty liver disease (NAFLD) remains uncertain. We aimed to explore the associations between a healthy lifestyle and higher LE8 scores with new-onset severe NAFLD in the general population. METHODS: 266,645 participants without prior liver diseases were included from the UK Biobank. A healthy lifestyle was determined based on body mass index, smoking, alcohol consumption, physical activity, sleep duration, and diet...
June 26, 2023: Metabolism: Clinical and Experimental
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.